Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 11; no. 1; pp. 2806 - 7
Main Authors Poh, Chek Meng, Carissimo, Guillaume, Wang, Bei, Amrun, Siti Naqiah, Lee, Cheryl Yi-Pin, Chee, Rhonda Sin-Ling, Fong, Siew-Wai, Yeo, Nicholas Kim-Wah, Lee, Wen-Hsin, Torres-Ruesta, Anthony, Leo, Yee-Sin, Chen, Mark I-Cheng, Tan, Seow-Yen, Chai, Louis Yi Ann, Kalimuddin, Shirin, Kheng, Shirley Seah Gek, Thien, Siew-Yee, Young, Barnaby Edward, Lye, David C., Hanson, Brendon John, Wang, Cheng-I, Renia, Laurent, Ng, Lisa F. P.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.06.2020
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text
ISSN2041-1723
2041-1723
DOI10.1038/s41467-020-16638-2

Cover

More Information
Summary:Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus. Characterisation of the human antibody response to SARS-CoV-2 can help the design of serological tests and vaccines. Here, the authors identify two linear epitopes in SARS-CoV-2 spike protein that elicit neutralising antibodies in several patients and could thus be useful for serology and vaccine development.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-020-16638-2